argenx SE (ARGX) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for argenx SE, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track ARGX live on Mooboard →

Next 30 days1

  • Sep 2026
    argenx SE(ARGX)Phase 2/3 readout
    Empasiprubart · Phase 3 · Multifocal Motor Neuropathy (MMN); MMN
    NCT06742190: A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days3

  • Sep 30, 2026
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 2 / Phase 3 · Generalized Myasthenia Gravis
    NCT06392386: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis. Primary completion 2026-09-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 1, 2026
    argenx SE(ARGX)Phase 2/3 readout
    efgartigimod PH20 SC · Phase 3 · Primary Immune Thrombocytopenia
    NCT04812925: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2026
    argenx SE(ARGX)Phase 2/3 readout
    Empasiprubart IV · Phase 2 · Dermatomyositis; Myositis
    NCT06284954: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later20

  • Feb 2027
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 2 · Systemic Sclerosis (SSc)
    NCT06655155: A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis. Primary completion 2027-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2027
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod IV · Phase 2 / Phase 3 · Generalized Myasthenia Gravis
    NCT04833894: Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis. Primary completion 2027-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 2 · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    NCT04280718: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves). Primary completion 2027-04-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 2027
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 3 · Primary Sjogrens Disease
    NCT06684847: A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome. Primary completion 2027-07 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2027
    argenx SE(ARGX)Phase 2/3 readout
    empasiprubart · Phase 3 · Chronic Inflammatory Demyelinating Polyneuropathy; CIDP
    NCT06920004: A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP. Primary completion 2027-09 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2027
    argenx SE(ARGX)Phase 2/3 readout
    Empasiprubart IV · Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG)
    NCT07673627: ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis. Primary completion 2027-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 7, 2027
    argenx SE(ARGX)Phase 2/3 readout
    Empasiprubart IV · Phase 3 · Chronic Inflammatory Demyelinating Polyneuropathy; CIDP
    NCT07091630: A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP. Primary completion 2027-10-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 2027
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC - prefilled syringe · Phase 2 · Antibody-mediated Rejection
    NCT06503731: A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR). Primary completion 2027-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 7, 2028
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod IV · Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis
    NCT07284420: ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod. Primary completion 2028-03-07 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 2028
    argenx SE(ARGX)Phase 2/3 readout
    Empasiprubart IV · Phase 2 / Phase 3 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy; CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
    NCT07638566: A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Primary completion 2028-04 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod IV · Phase 3 · Primary Immune Thrombocytopenia (ITP)
    NCT06544499: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia. Primary completion 2028-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    argenx SE(ARGX)Phase 2/3 readout
    efgartigimod PH20 SC · Phase 3 · Graves Disease
    NCT07596849: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.. Primary completion 2028-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2028
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 3 · Graves' Disease; Graves Disease
    NCT07570316: A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. Primary completion 2028-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2028
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 SC · Phase 3 · Myositis; Active Idiopathic Inflammatory Myopathy
    NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy. Primary completion 2028-09 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Oct 2028
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod IV · Phase 2 / Phase 3 · Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia
    NCT07194850: A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP). Primary completion 2028-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 20, 2029
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod PH20 (ARGX-113) SC · Phase 2 · Autoimmune Encephalitis (AE)
    NCT07583641: A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults. Primary completion 2029-01-20 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • May 28, 2029
    argenx SE(ARGX)Phase 2/3 readout
    ARGX-119 IV · Phase 2 · Spinal Muscular Atrophy (SMA)
    NCT07287982: A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy. Primary completion 2029-05-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 2029
    argenx SE(ARGX)Phase 2/3 readout
    Efgartigimod IV or Efgartigimod PH20 SC · Phase 2 / Phase 3 · Generalized Myasthenia Gravis; gMG
    NCT05374590: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis. Primary completion 2029-09 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Sep 30, 2029
    argenx SE(ARGX)Phase 2/3 readout
    ARGX-117 · Phase 2 · Multifocal Motor Neuropathy (MMN)
    NCT05405361: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy. Primary completion 2029-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2030
    argenx SE(ARGX)Phase 2/3 readout
    Adimanebart IV · Phase 3 · Congenital Myasthenic Syndrome; CMS
    NCT07746089: A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS). Primary completion 2030-10 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How argenx SE has moved — past-year price reactions

How binary is ARGX? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.2%
typical day (1Y)
0
±10% days
30.7%
annualized vol
250
trading days
Largest single-day moves
  • +8.6%2026-07-23no matched headline
  • +5.8%2026-06-05no matched headline
  • -5.6%2026-06-23no matched headline
  • -5.6%2026-02-26no matched headline
  • -4.7%2026-01-05no matched headline
  • +4.5%2025-08-26no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

argenx SE — active clinical pipeline

argenx SE's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

12 assets30 programsPh1 5Ph2 9Ph3 15· 1 post-marketing (Ph4)
AreasAutoimmuneImmunologyNeuroscienceRare / GeneticOther
Efgartigimod PH20 SCAutoimmune
Phase 2
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3
Generalized Myasthenia GravisGraves DiseaseGraves' DiseaseMyositisPrimary Immune ThrombocytopeniaPrimary Sjogrens Disease
Empasiprubart IVImmunology
Phase 1
Multifocal Motor Neuropathy (MMN)
Phase 2
AChR-Ab Seropositive Generalized Myasthenia GravisDermatomyositis
Phase 3
Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating Polyradiculoneuropathy
Efgartigimod IVAutoimmune
Phase 2
AChR-Ab Seropositive Generalized Myasthenia Gravis
Phase 3
Generalized Myasthenia Gravis (2)Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)
Adimanebart IVOther
Phase 1
Healthy volunteers
Phase 3
Congenital Myasthenic Syndrome
EmpasiprubartNeuroscience
Phase 3
Chronic Inflammatory Demyelinating PolyneuropathyMultifocal Motor Neuropathy (MMN)
Efgartigimod IV or Efgartigimod PH20 SCAutoimmune
Phase 3
Generalized Myasthenia Gravis
ARGX-117Immunology
Phase 2
Delayed Graft FunctionMultifocal Motor Neuropathy (MMN)
ARGX-119Neuroscience
Phase 1
Congenital Myasthenic Syndrome
Phase 2
Amyotrophic Lateral Sclerosis
ARGX-119 IVRare / Genetic
Phase 2
Spinal Muscular Atrophy (SMA)
Efgartigimod PH20 (ARGX-113) SCAutoimmune
Phase 2
Autoimmune Encephalitis (AE)
ARGX-124Other
Phase 1
Healthy volunteers
empasiprubart SC AIOther
Phase 1
Healthy volunteers

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.